Kimberly-Clark
KMB
$97.74
+1.31%
Kimberly-Clark Corp. is a global consumer staples manufacturer operating in the household and personal products industry, with a portfolio anchored by iconic brands such as Huggies, Kleenex, Kotex, Depend, Pull-Ups, and Cottonelle. Roughly half of its sales come from personal care and another third from consumer tissue, with the remainder in professional workplace hygiene solutions, and it generates just over half its revenue in North America plus more than 10% in Europe. The company is a mature, dividend-focused large-cap whose investor narrative is currently dominated by its pending acquisition of Kenvue's consumer health portfolio, expected to close in the second half of calendar 2026, which would meaningfully reshape its category mix. At the same time, the stock has been a notable laggard, with a roughly 4.9% dividend yield and a deeply discounted valuation drawing income-oriented attention even as analysts debate integration risk, soft organic growth, and a heavy debt load.…
KMB
Kimberly-Clark
$97.74
Related headlines
Investment Opinion: Should I buy KMB Today?
The synthesized recommendation is Hold. KMB offers a compelling 4.94% dividend yield and trades at a deep discount to peers, but the stagnant organic growth, elevated leverage, and integration risks surrounding the Kenvue acquisition create a balanced risk/reward profile. The analyst consensus rating of 'buy' with an average target price of $116.20 implies 23.1% upside, but the wide target range ($90-$162) and the stock's severe downtrend suggest that the upside is contingent on successful execution.
Supporting evidence for a Hold includes the forward PE of 12.61x, which is roughly 40-45% below the consumer staples sector average, and a price-to-sales ratio of 1.95x, which is modest for a branded staples company. The dividend yield of 4.94% is attractive, and free cash flow of $2.561 billion provides coverage, though the payout ratio of 82.14% is high. Revenue growth of just 0.62% year-over-year is a concern, but the Kenvue acquisition could provide a step-change in earnings power, as reflected in the forward EPS estimate of $8.79 versus trailing EPS of $0.06 (GAAP). The stock's beta of 0.273 makes it a defensive holding, but its recent underperformance (-23.05% over one year) shows that company-specific risks dominate.
The biggest risks that could invalidate the thesis are integration missteps with Kenvue, a dividend cut if earnings decline, and continued organic stagnation. The rating would upgrade to Buy if the Kenvue deal closes smoothly and organic growth accelerates above 2%, or if the forward PE compresses below 12x with improving margins. It would downgrade to Sell if revenue growth turns negative, the dividend is cut, or debt-to-equity rises above 5.5x. Relative to its history and peers, KMB appears undervalued on a forward basis, but the discount is warranted by its weak growth and high leverage, making it fairly valued at best until catalysts materialize.
Sign up to view all
KMB 12-Month Price Forecast
KMB presents a balanced risk/reward profile, with the deep valuation discount and high dividend yield offset by stagnant organic growth and integration risks. The stock's severe underperformance (-23.05% over one year) and position near its 52-week low suggest that negative sentiment is already priced in, but a catalyst is needed to reverse the trend. The Kenvue acquisition is the key swing factor: successful integration could drive a re-rating toward peer multiples, while missteps could lead to further downside. I would upgrade to bullish if the deal closes smoothly and organic growth accelerates above 2%, or downgrade to bearish if revenue turns negative or the dividend is cut. Given the low beta and defensive characteristics, the stock is suitable for income-oriented investors willing to tolerate near-term volatility.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $115.87 and implied upside of +18.6% versus the current price.
Average Target
$115.87
0 analysts
Implied Upside
+18.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
Fifteen analysts cover Kimberly-Clark, with a consensus recommendation of "buy" and a recommendation mean of 2.44, which on a typical 1-to-5 scale (1 = strong buy, 5 = strong sell) leans moderately bullish. The average price target is $116.20, implying 23.1% upside from the current price of $94.36, while the consensus forward EPS estimate of $8.79 and revenue estimate of $35.77 billion suggest analysts expect a meaningful earnings recovery. The bullish tilt is notable given the stock's 23.05% one-year decline, indicating that the sell-side views the weakness as overdone and the Kenvue acquisition as a value-creating catalyst.
The target range is wide, from a low of $90.00 to a high of $162.00, a spread of 80% that signals substantial disagreement about the company's trajectory. The high target of $162.00 implies roughly 72% upside and would require successful Kenvue integration, margin expansion, and a re-rating toward historical peak multiples, while the low target of $90.00 — 4.6% below the current price — prices in integration missteps, continued organic stagnation, or dividend pressure from the elevated payout ratio. Recent institutional ratings show a mix of Buy/Overweight (B of A, Piper Sandler) and Neutral/Equal Weight/Hold (Wells Fargo, TD Cowen, UBS, Barclays), with no recent upgrades or downgrades, suggesting analysts are in a holding pattern awaiting deal closure. The wide spread and the clustering of ratings around neutral-to-buy indicate moderate conviction: the upside is real but contingent on execution, and the stock's low beta of 0.273 means the risk is idiosyncratic rather than market-driven.
Bulls vs Bears: KMB Investment Factors
The bear case currently has stronger evidence, driven by KMB's severe price downtrend, stagnant organic growth, and elevated leverage, which are concrete and immediate. The bull case rests largely on the pending Kenvue acquisition and a deeply discounted forward valuation, both of which are prospective and contingent on successful execution. The single most important tension is whether the Kenvue deal will close smoothly and deliver the expected earnings accretion, or whether integration risks and a heavy debt load will overwhelm the company's defensive characteristics. Until there is clear evidence of successful integration or a reversal in the price trend, the risk/reward remains skewed to the downside despite the attractive dividend yield.
Bullish
- Deeply discounted forward valuation: KMB trades at a forward PE of 12.61x versus a trailing PE of 16.59x, a 24% discount that implies the market expects meaningful earnings growth. Relative to consumer staples peers that typically trade in the low-to-mid 20s on forward earnings, KMB's multiple is roughly 40-45% below the sector, offering substantial re-rating potential if the Kenvue deal delivers.
- High dividend yield with FCF coverage: The stock yields 4.94%, well above the S&P 500 average, backed by trailing free cash flow of $2.561 billion and a 7.6% FCF yield on the $33.6 billion market cap. While the payout ratio of 82.14% is elevated, the consistent cash generation provides a cushion for the dividend even as the company integrates Kenvue.
- Analyst consensus sees 23% upside: Fifteen analysts rate KMB a 'buy' with a recommendation mean of 2.44 and an average price target of $116.20, implying 23.1% upside from the current $94.36. The bullish tilt persists despite a 23.05% one-year decline, suggesting the sell-side views the weakness as overdone and the Kenvue acquisition as a value-creating catalyst.
- Kenvue acquisition as growth catalyst: The pending acquisition of Kenvue's consumer health portfolio, expected to close in H2 2026, would meaningfully reshape KMB's category mix and provide a step-change in earnings power. Analysts' forward EPS estimate of $8.79 versus trailing EPS of $0.06 (GAAP) reflects this expected inflection, and successful integration could drive a re-rating toward peer multiples.
Bearish
- Severe price downtrend and underperformance: KMB is down 23.05% over the past year and 6.94% year-to-date, massively underperforming the S&P 500's 15.01% one-year gain. The stock sits just 1.9% above its 52-week low of $92.42 and only 23.5% of the way up its annual range, signaling persistent distribution and negative momentum.
- Stagnant organic revenue growth: Q2 2026 revenue of $4.189 billion grew just 0.62% year-over-year, and the multi-quarter trend is flat to slightly negative. With no meaningful organic growth, the company relies entirely on the Kenvue acquisition to drive top-line expansion, leaving little margin for integration missteps.
- Elevated leverage and thin liquidity: Debt-to-equity stands at 4.86x, the current ratio is a thin 0.745, and the payout ratio is 82.14%, leaving limited cushion for the dividend if earnings decline. The heavy debt load also increases financial risk as the company prepares to fund the Kenvue integration.
- Profitability under pressure: Q2 2026 net income fell to $345 million (8.24% net margin) from $509 million in Q2 2025, and operating margin of 10.69% was well below Q3 2025's 15.03%. The compression in net income year-over-year is a yellow flag for a defensive staple and raises questions about earnings quality.
KMB Technical Analysis
Kimberly-Clark is in a clear, sustained downtrend, with the shares down 23.05% over the past year and 6.94% year-to-date, a stark contrast to the S&P 500's 15.01% one-year gain. At a current price of $94.36, the stock sits at just 1.9% above its 52-week low of $92.42 and only 23.5% of the way up its 52-week range of $92.42 to $123.38, meaning it is pinned near the bottom of its annual band. That positioning signals persistent distribution and negative momentum rather than a value opportunity being confirmed by price action, and the relative strength of -38.06% versus SPY over one year underscores how severe the underperformance has been.
Short-term momentum has deteriorated sharply and is diverging negatively from the already weak longer-term trend. The stock is down 13.66% over the past month and 17.75% over three months, versus a 1-month gain of 0.59% and 3-month gain of 3.34% for SPY, producing relative strength readings of -14.25% and -21.09% respectively. The 6-month change of -1.84% versus the 1-year change of -23.05% shows that most of the damage occurred in the first half of the period, but the recent acceleration lower — including a drop from $109.29 on September 2 to $94.36 on October 2 — indicates fresh selling pressure rather than stabilization. With a short ratio of 12.32, bears appear positioned for further weakness, and the stock's beta of 0.273 means it is far less volatile than the market, so this decline is company-specific rather than macro-driven.
Key technical levels are now tightly defined: support sits at the 52-week low of $92.42, just 2.1% below the current price, while resistance is anchored at the 52-week high of $123.38, roughly 30.8% above. A breakdown below $92.42 would mark a fresh 52-week low and likely trigger momentum-driven selling, whereas a reclaim of even the $100-$102 area would be the first sign of stabilization. The maximum drawdown of -28.95% and the low beta of 0.273 matter for risk management: the stock's defensive characteristics have not protected it from a stock-specific de-rating, so position sizing should account for the possibility that the downtrend persists until a catalyst — most likely the Kenvue deal closing — changes the narrative.
Beta
0.28
0.28x market volatility
Max Drawdown
-28.9%
Largest decline past year
52-Week Range
$92-$123
Price range past year
Annual Return
-18.3%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | -5.0% | +1.0% |
| 3m | -13.1% | +2.5% |
| 6m | +0.5% | +13.9% |
| 1y | -18.3% | +15.0% |
| ytd | -3.6% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue growth has effectively stalled, with Q2 2026 revenue of $4.189 billion representing just 0.62% year-over-year growth versus Q2 2025's $4.163 billion. The multi-quarter trend is flat to slightly negative: revenue was $4.163 billion in Q1 2026, $4.080 billion in Q4 2025, $4.133 billion in Q3 2025, and $4.840 billion in Q1 2025, so the year-over-year comparisons are being flattered by an unusually strong prior-year first quarter that has not been repeated. Within the segment mix, diapers at $1.752 billion and consumer tissue at $1.015 billion are the largest contributors, while adult care at $493 million, feminine care at $423 million, and away-from-home professional products at $476 million are smaller but higher-margin opportunities. The pending Kenvue consumer health acquisition is the primary growth lever, but until it closes, the organic trajectory implies a low-single-digit growth profile that limits multiple expansion.
Profitability remains solid but is showing signs of pressure. Q2 2026 net income was $345 million on a net margin of 8.24%, down sharply from Q1 2026's $665 million and 15.97% net margin, and below Q2 2025's $509 million. Gross margin in Q2 2026 was 38.27%, an improvement from 36.85% in Q1 2026 and 35.91% in Q4 2025, and above the 34.97% recorded in Q2 2025, suggesting input cost relief and pricing are supporting the top line of the P&L. However, operating margin of 10.69% in Q2 2026 was below Q1 2026's 11.41% and well below Q3 2025's 15.03%, and the trailing operating margin of 14.46% versus a net margin of 11.74% shows that below-the-line items and taxes are consuming a meaningful share of profit. The company remains comfortably profitable, but the compression in net income year-over-year is a yellow flag for a defensive staple.
Balance sheet leverage is the most significant fundamental risk. Debt-to-equity stands at 4.86x, the current ratio is a thin 0.745, and the company carries a payout ratio of 82.14% against a 4.94% dividend yield, leaving limited cushion for the dividend if earnings decline. Free cash flow on a trailing-twelve-month basis is $2.561 billion, and Q2 2026 free cash flow was $556 million after $352 million of capital expenditure, while Q1 2026 free cash flow was just $321 million after $424 million of capex. ROE of 134.55% is inflated by the very small equity base created by leverage, and with cash of only $1.363 billion at the end of Q2 2026 against substantial debt, the company depends on consistent operating cash flow — $908 million in Q2 2026 — to fund both the dividend and the coming Kenvue integration. The FCF yield of roughly 7.6% on the $33.6 billion market cap is attractive, but the leverage profile means financial risk is elevated relative to typical consumer staples peers.
Quarterly Revenue
$4.2B
2026-06
Revenue YoY Growth
+0.6%
YoY Comparison
Gross Margin
38.3%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Because Kimberly-Clark is solidly profitable — Q2 2026 net income of $345 million and trailing EPS of $0.06 on a GAAP basis but roughly $8.79 on a forward adjusted basis — the PE ratio is the appropriate primary metric. The trailing PE of 16.59x compares with a forward PE of 12.61x, a 24% discount that implies the market expects meaningful earnings growth, likely driven by the Kenvue acquisition and cost synergies rather than organic momentum. The gap between trailing and forward multiples is unusually wide for a staple, suggesting the market is pricing in a step-change in earnings power that has yet to be proven.
Relative to the broader consumer defensive sector, which typically trades in the low-to-mid 20s on forward earnings, Kimberly-Clark's 12.61x forward PE represents a substantial discount of roughly 40-45%. The price-to-sales ratio of 1.95x and EV/EBITDA of 12.94x are also modest for a branded staples company, though the EV/EBITDA is elevated by the heavy debt load embedded in enterprise value. The discount appears justified by the company's near-zero organic growth, 4.86x debt-to-equity, and integration risk around Kenvue, but it also means that any evidence of successful integration or margin recovery could drive a re-rating toward peer multiples.
Historically, Kimberly-Clark's PE has ranged widely, from a low of about 12.06x in Q1 2026 to a high of 26.39x in Q2 2026 on a trailing basis, with the current 16.59x sitting in the lower-middle portion of that band. The price-to-book ratio of 22.37x is near the low end of its historical range of roughly 17.8x to 93.3x, reflecting the compressed equity base and the stock's de-rating. The current valuation is not at an extreme low, but it is closer to the bottom of the historical band than the top, which suggests the market has already priced in considerable pessimism — leaving room for upside if the Kenvue deal closes smoothly and earnings inflect.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, primarily due to KMB's elevated leverage and thin liquidity. Debt-to-equity stands at 4.86x, the current ratio is a mere 0.745, and the payout ratio is 82.14%, leaving little room for error if earnings decline. The company's Q2 2026 net income fell to $345 million from $509 million a year earlier, and operating margin compressed to 10.69% from 15.03% in Q3 2025, highlighting earnings volatility. With free cash flow of $2.561 billion trailing, the company must balance dividend payments, capital expenditures, and the upcoming Kenvue integration, which could strain financial flexibility.
Market and competitive risks are heightened by KMB's premium valuation relative to its growth profile and the potential for multiple compression. The stock trades at a forward PE of 12.61x, which is a discount to staples peers, but the discount is justified by near-zero organic growth and integration risk. The low beta of 0.273 means the stock is less sensitive to macro factors, but it also means company-specific issues can drive severe underperformance, as evidenced by the 23.05% one-year decline. Competitive pressures in the tissue and hygiene space, particularly from private-label brands and rivals like Procter & Gamble, could further erode market share. Recent news highlights integration risks surrounding the Kenvue deal, with analysts warning of near-term volatility.
A worst-case scenario would involve the Kenvue acquisition failing to deliver expected synergies, leading to earnings dilution and a dividend cut. This could trigger a breakdown below the 52-week low of $92.42, with the stock potentially falling to the analyst low target of $90, representing a 4.6% decline from the current price. In a more severe scenario, if integration missteps coincide with a recession, the stock could retest its historical max drawdown of -28.95%, implying a drop to around $67, a loss of roughly 29% from current levels. The low beta may not provide much protection in a company-specific crisis, and the high short ratio of 12.32 suggests bears are positioned for further weakness.
FAQ
The most severe risk is integration risk surrounding the Kenvue acquisition, which could lead to earnings dilution and a dividend cut if synergies are not realized. Financial risk is elevated, with debt-to-equity at 4.86x, a current ratio of 0.745, and a payout ratio of 82.14%, leaving little cushion for a downturn. Competitive risk is also a concern, as private-label brands and rivals like Procter & Gamble could pressure market share in the tissue and hygiene space. Macro risk is relatively low given the beta of 0.273, but a recession could still reduce consumer spending on discretionary hygiene products. Additionally, the stock's severe underperformance (-23.05% over one year) and high short ratio of 12.32 suggest that negative sentiment could persist.
The 12-month forecast is based on three scenarios: a bull case with 25% probability targeting $123.38-$162.00, a base case with 55% probability targeting $110-$120, and a bear case with 20% probability targeting $90-$92.42. The base case is most likely, assuming the Kenvue acquisition closes with moderate integration challenges and organic growth remains low-single-digit, leading to a stock price around the analyst average target of $116.20. The bull case requires smooth integration and accelerating organic growth, while the bear case assumes integration missteps and a dividend cut. The key assumption behind the base case is that forward EPS meets the consensus estimate of $8.79 and the dividend is maintained, supporting a valuation in line with historical averages.
KMB appears undervalued on a forward basis, with a forward PE of 12.61x compared to a trailing PE of 16.59x and a consumer staples sector average in the low-to-mid 20s. The price-to-sales ratio of 1.95x and EV/EBITDA of 12.94x are also modest for a branded staples company, though the EV/EBITDA is elevated by the heavy debt load. The market is pricing in a step-change in earnings power from the Kenvue acquisition, as evidenced by the 24% gap between trailing and forward multiples. However, the discount is justified by near-zero organic growth and integration risk, so the stock is fairly valued at best until there is evidence of successful execution. If the Kenvue deal delivers, the multiple could expand toward peer levels, implying significant upside.
KMB offers a compelling 4.94% dividend yield and trades at a forward PE of 12.61x, roughly 40-45% below consumer staples peers, which may appeal to income-focused investors. However, the company's organic revenue growth is just 0.62% year-over-year, and its debt-to-equity of 4.86x and payout ratio of 82.14% raise concerns about financial flexibility. The analyst consensus target of $116.20 implies 23.1% upside, but the wide range ($90-$162) and the stock's 23.05% one-year decline suggest significant uncertainty. The biggest downside risk is integration missteps with the Kenvue acquisition, which could lead to a dividend cut and further price depreciation. For risk-averse investors seeking stable income, KMB may be a good buy on weakness, but only if they are comfortable with the execution risk and can tolerate near-term volatility.
KMB is more suitable for long-term investment, particularly for income-oriented investors seeking a high dividend yield and low volatility. The stock's beta of 0.273 and 4.94% dividend yield make it a defensive holding, but the pending Kenvue acquisition introduces near-term uncertainty that could lead to volatility. Short-term trading is not advisable given the strong downtrend and the lack of a clear catalyst until the deal closes. A minimum holding period of 2-3 years is recommended to allow for integration synergies to materialize and for the dividend to provide compounding returns. Investors should monitor the acquisition closing and organic growth trends before considering a position.